Sucrosomial iron

Sucrosomial iron is a new oral iron preparation containing ferric pyrophosphate covered by phospholipids plus sucrose ester of fatty acid matrix. This allows the molecule to be absorbed in the gastrointestinal tract by trans-cellular, para-cellular and M-cells independently of hepcidin and due to gastro-resistant properties, it does not cause the side effects such as gastric irritation which is commonly associated to oral iron.^[1]^[2]^[3]

References[edit]

^ Gascon, Pere (2012-10-31), "Bone Marrow Toxicity: Red Blood Cells", Side Effects of Medical Cancer Therapy, Springer London, pp. 333–364, doi:10.1007/978-0-85729-787-7_8, ISBN 978-0-85729-786-0, retrieved 2020-04-08
^ Gómez-Ramírez, Susana; Brilli, Elisa; Tarantino, Germano; Muñoz, Manuel (2018-10-04). "Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation". Pharmaceuticals. 11 (4): 97. doi:10.3390/ph11040097. ISSN 1424-8247. PMC 6316120. PMID 30287781.
^ Michalak, Sylwia Sulimiera (2020-12-01). "Iron deficiency anemia – new possibilities of iron supplementation in various clinical conditions". Acta Haematologica Polonica. 51 (4): 212–219. doi:10.2478/ahp-2020-0037.

[1] Gascon, Pere (2012-10-31), "Bone Marrow Toxicity: Red Blood Cells", Side Effects of Medical Cancer Therapy, Springer London, pp. 333–364, doi:10.1007/978-0-85729-787-7_8, ISBN 978-0-85729-786-0, retrieved 2020-04-08

[2] Gómez-Ramírez, Susana; Brilli, Elisa; Tarantino, Germano; Muñoz, Manuel (2018-10-04). "Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation". Pharmaceuticals. 11 (4): 97. doi:10.3390/ph11040097. ISSN 1424-8247. PMC 6316120. PMID 30287781.

[3] Michalak, Sylwia Sulimiera (2020-12-01). "Iron deficiency anemia – new possibilities of iron supplementation in various clinical conditions". Acta Haematologica Polonica. 51 (4): 212–219. doi:10.2478/ahp-2020-0037.

[1]

[2]

[3]